Navigation Links
Myelodysplastic in Medical News
Randomized Comparator Study to Evaluate Efficacy of Commercially Available Hypomethylating Agents
WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswire/ -- Eisai Corporation of North America today announced that it plans to initiate the first clinical trial evaluating the activity of Dacogen(R) (deci...
* Recommended Phase II Dose of MGCD0103 Determined as 90 mg * 53% of Patients Treated with 90 mg Dose Achieved a Clinical Response * Patients with Responses Experienced a 66% Reduction in the Risk of Death Compared to Non-responders ATLANTA, Dec. 10 /PRNewswire-...
PALO ALTO, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) announced positive results from the multicenter Phase 1 dose-escalation study of TELINTRA(R) (ezatiostat HCl) Tablets in myelodysplastic syndrome (MDS) that support the initiation of Phase 2 clinical trials. The d...
...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's...
... therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy...
A new agent for the treatment of patients with myelodysplastic syndrome; and more
A new agent for the treatment of patients with myelodysplastic syndrome In a paper published this week in PLoS Medicine, Azra Raza and colleagues (University of Massachusetts) use gene expression profiling to identify a molecular signature that predicts response to lenalidomide in patients wi...* Recommended Phase II Dose of MGCD0103 Determined as 90 mg * 53% of Patients Treated with 90 mg Dose Achieved a Clinical Response * Patients with Responses Experienced a 66% Reduction in the Risk of Death Compared to Non-responders ATLANTA, Dec. 10 /PRNewswire-...
PALO ALTO, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) announced positive results from the multicenter Phase 1 dose-escalation study of TELINTRA(R) (ezatiostat HCl) Tablets in myelodysplastic syndrome (MDS) that support the initiation of Phase 2 clinical trials. The d...
Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
A new drug treatment, Revlimid for treatment of myelodysplastic syndrome (MDS), a rare blood disorder has been approved by the Food and Drug Administration (FDA). The approval was announced by Celgene Corp, manufacturer of the drug.// The exact cause of MDS is not known. However, increased i...Drug increases hemoglobin in Myelodysplastic Syndrome
Patients with Bone marrow disorder Myelodysplastic Syndrome (MDS), treated with 500 mcg of Aranesp (Darbepoetin alfa) for every three weeks found to improve the hemoglobin content in 70% of patients. //The new drug Aranesp is manufactured by Amgen Biotech, which conducted a Phase II trial with 200 ...New Report Just Published: World Multiple Myeloma Therapeutics Market Report
...te Myeloid Leukemia, Chronic Myeloid Leukemia, and Other Leukemia), and myelodysplastic Syndromes (MDS) (includes corresponding Graph/Chart) II-3 Table 2:...oma II-31 Non-Hodgkin's Lymphoma II-32 Hodgkin's Lymphoma II-32 myelodysplastic Syndromes II-32 Hematological Cancer Therapies II-33 Chemotherapy I......advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's...
... therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy...
Telik Announces Preclinical Presentations at AACR Annual Meeting
...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Teli...Myelodysplastic in Medical Technology
PALO ALTO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) today announced that the positive results from a Phase 1 multicenter, dose escalation study of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with Myelodysplastic Syndrome (MDS) have been p...
WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an alternative five-day dosing regimen for Dacogen(R) (decitabine for ...
Submission of Five-Day Dosing Regimen sNDA Targeted for Fiscal Year-end 2008 WOODCLIFF LAKE, N.J., July 1, 2008 /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in 2002 comparing Dacogen(R) ...
Reiterates 2008 Annual Financial Guidance DUBLIN, Calif., July 1 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, tod...
NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with acute myelogenous leukemia (AML) and high-risk m...
- MAA submission based on data from largest Phase 3 study conducted in MDS - Vidaza therapy confers highly significant 9.4 month median overall survival advantage compared to conventional care regimens - Two year overall survival rate of 50.8% for Vidaza compared to 26.2% for ...
Two year survival rate of 50.8 percent for Vidaza versus 26.2 for conventional care regimens 9.4 months median survival benefit for patients on Vidaza compared to conventional care regimens Only agent to demonstrate survival benefit in MDS compa...
Moffitt Research Presented at 9th International Symposium on Myelodysplastic Syndromes TAMPA, Fla., May 17, 2007 /PRNewswire/ -- New updated results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) were presented ...
WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an alternative five-day dosing regimen for Dacogen(R) (decitabine for ...
Submission of Five-Day Dosing Regimen sNDA Targeted for Fiscal Year-end 2008 WOODCLIFF LAKE, N.J., July 1, 2008 /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in 2002 comparing Dacogen(R) ...
Reiterates 2008 Annual Financial Guidance DUBLIN, Calif., July 1 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, tod...
NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with acute myelogenous leukemia (AML) and high-risk m...
- MAA submission based on data from largest Phase 3 study conducted in MDS - Vidaza therapy confers highly significant 9.4 month median overall survival advantage compared to conventional care regimens - Two year overall survival rate of 50.8% for Vidaza compared to 26.2% for ...
Two year survival rate of 50.8 percent for Vidaza versus 26.2 for conventional care regimens 9.4 months median survival benefit for patients on Vidaza compared to conventional care regimens Only agent to demonstrate survival benefit in MDS compa...
Moffitt Research Presented at 9th International Symposium on Myelodysplastic Syndromes TAMPA, Fla., May 17, 2007 /PRNewswire/ -- New updated results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) were presented ...
Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
- Analysis of Phase III Data Presented at ASCO - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Investigators reported today that Soliris(TM) (eculizumab), a new treatment for paroxysmal nocturnal hemoglobinuria (PNH) developed by Alexion Pharmaceuticals, Inc. , is effective in patients diagnose...Telik Announces Presentation at ASCO Annual Meeting
...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's...Myelodysplastic in Medical Definition
...of Hematopoietic Cells
The major disease of hematopoietic cells fall into several categories, which include chronic myeloproliferative disease , myelodysplastic syndromes , leukemias , lymphomas , plasma cell neoplasms , and histiocytic and mast cell neoplasms. Hematopathologists from all over the world h...
Myelodysplastic in Medical Dictionary
...diseases ("MPD"s) are a group of diseases of the bone marrow in which excess cells are produced. They are related to, and may evolve into, myelodysplastic syndrome and acute myeloid leukemia, although the myeloproliferative diseases on the whole... Myeloproliferative disorders , Myeloprolif...
...dents, and to provide graduate students in epidemiology with training that will allow them ... Descriptive Epidemiology and Clinical Course of myelodysplastic Syndromes within ... Genetic Epidemiology of Prostate Cancer (PROGRESS) (Stanford) ... Introduces the basic principles and methods of epidemiol...
...ome cases of aplastic anemia are linked to benzene exposure, see our At ... Assists patients and families dealing with aplastic anemia and myelodysplastic syndromes. More about Aplastic Anemia : Causes and symptoms Diagnosis Treatment Prognosis Resources Aplastic Anemia Definition Aplastic ...
...gation Page. New ... In acquired aplastic anemia, clinical and laboratory ... Assists patients and families dealing with aplastic anemia and myelodysplastic syndromes. Aplastic anemia — Comprehensive overview covers symptoms, causes, treatment of this rare blood disorder. ... and serious condit...
...dents, and to provide graduate students in epidemiology with training that will allow them ... Descriptive Epidemiology and Clinical Course of myelodysplastic Syndromes within ... Genetic Epidemiology of Prostate Cancer (PROGRESS) (Stanford) ... Introduces the basic principles and methods of epidemiol...
...ome cases of aplastic anemia are linked to benzene exposure, see our At ... Assists patients and families dealing with aplastic anemia and myelodysplastic syndromes. More about Aplastic Anemia : Causes and symptoms Diagnosis Treatment Prognosis Resources Aplastic Anemia Definition Aplastic ...
...gation Page. New ... In acquired aplastic anemia, clinical and laboratory ... Assists patients and families dealing with aplastic anemia and myelodysplastic syndromes. Aplastic anemia — Comprehensive overview covers symptoms, causes, treatment of this rare blood disorder. ... and serious condit...
Myelodysplastic in Biological News
The MDS foundation supports vidaza's recommendation for European approval
... The myelodysplastic Syndromes (MDS) Foundation supports the positive opinion from the European ...ing approval for VIDAZA," said Kathy Heptinstall, Operating Director of the myelodysplastic Syndromes Foundation, "The MDS Foundation is committed to making sure that ...Vidaza receives positve opinion from European CHMP
...P) has awarded Vidaza (azacitidine) a positive opinion for the treatment of myelodysplastic syndromes (MDS) patients who are not eligible for stem cell transplants. ... approval shortly and quickly be available for patients across Europe." myelodysplastic syndromes (MDS) occur when the bone marrow stem cells malfunction. This re...The MDS Foundation supports the FDA's decision to expand vidaza label to include survival data
... Crosswicks, NJ (August 22, 2008) The myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Ad...ts with higher-risk MDS," said Kathy Heptinstall, Operating Director of the myelodysplastic Syndromes Foundation, "Roughly 30 percent of patients diagnosed with MDS wi...Weill Cornell science briefs June/July 2008
... shrunk to normal sizes, and they began to produce normal red blood cells. The chemical (a similar compound is already in a Phase I clinical trial for myelodysplastic syndromes -- another blood disorder) blocks the activity of the JAK2 gene that is highly expressed in Cooley's anemia, and is believed to play a cruci...Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf
... shrunk to normal sizes, and they began to produce normal red blood cells. The chemical (a similar compound is already in a Phase I clinical trial for myelodysplastic syndromes -- another blood disorder) blocks the activity of the JAK2 gene that is highly expressed in Cooley's anemia, and is believed to play a cruci...Ireland Cancer Center researchers advance stem cell gene therapy
...to show evidence that genetic mutations are accumulating in marrow stem cells. This finding might be the key underlying the increased risk of anemias, myelodysplastic syndrome and acute leukemia in older individuals. Dr. Kevin Buntings laboratory gave two important presentations on how intracellular STAT5 (a...NCI renewal grant to develop new cancer therapies
...f vorinostat, a histone deacetylase inhibitor, in combination with flavopiridol, a cell cycle inhibitor, in patients with refractory acute leukemia or myelodysplastic syndrome. Additionally, the team has recently received approval to lead a multi-institutional trial of vorinostat and bortezomib, a proteasome inh...New molecules discovered that block cancer cells from modifying cell DNA
...ions that work to reverse the methylation process in cancer cells. They include azacitine (Vidaza) and decitabine (Dacogen), both for the treatment of myelodysplastic syndrome, diseases in which the production of blood cells by the bone marrow is disrupted. Vorinostat (Zolinza) also works to turn back on silenced ge...New tool helps blood specialists improve patient care
...swering questions that determine compliance with pre-established performance measures developed by ASH that are important in the care of patients with myelodysplastic syndromes (MDS). "The hematologists who use these measures are not passive learners. They are not simply reading about how to improve patient care...Long-term cancer risk follows stem cell transplant recipients
...ls from a female donor. Myeloablative, allogeneic HSCT is an effective standard therapy for specific life-threatening diseases, such as leukemia or myelodysplastic syndrome, for which blood cell lineages (which originate principally in the bone marrow and circulate in the blood) are abnormal. Destroying the patie...Myelodysplastic in Biological Technology
Application to be reviewed under European Accelerated Assessment Procedure
BOULDER, Colo., Feb. 7 /PRNewswire-FirstCall/ -- Pharmion Corporation
(Nasdaq: PHRM ) today announced that the European Medicines Agency (EMEA)
has accepted for review the Company's Marketing Authorization Application
(...
... therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy...
...ients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndromes (MDS). (7, 8, 9). In patients with thrombosis of unknown origin,...mori T, et al. Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes. Br J Haematol. 1998;102 (2):465-474. (9) Maciejewski JP,...
Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
BOULDER, Colo., Aug. 29 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oral Azacitidine in the treatment of Myelodysplastic Syndromes (MDS). Fast Track programs are designe...Telik Announces Second Quarter 2009 Financial Results
...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Teli...... therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy...
Telik Reports Preclinical Results at AACR Annual Meeting
...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Teli...Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
...nderway: (i) the continuation of the pivotal Phase II trial; (ii) a Phase III trial with standard remission-induction therapy in patients with AML and myelodysplastic syndromes (MDS); (iii) a Phase I/II trial in combination with cytarabine in elderly patients with AML; and (iv) a Phase I/II trial in combination with...Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
...st advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Teli......ients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndromes (MDS). (7, 8, 9). In patients with thrombosis of unknown origin,...mori T, et al. Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes. Br J Haematol. 1998;102 (2):465-474. (9) Maciejewski JP,...
Telik Announces New TRAP Drug Discovery Agreement
...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik...Telik Announces Financial Results for 2008 Third Quarter
...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik...Other TagsOther Contents
(Date:5/21/2013)... May 21, 2013 Diversity Focus, a ... environments for all residents in the Creative Corridor region, ... Survey at a news conference on Thursday, May 23rd ... study, conducted in 2008. , The survey ... lead and support efforts that attract, nurture and retain ...
(Date:5/21/2013)... Healing Center announces their participation in the CannaCommunity Solutions ... including MedMar Healing Center, doctors, and clubs, are coming together ... raise food to help area kids who have been impacted ... , “We like being able to give back to ... of MedMar Healing Center. “Taking part in the food drive ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
(Date:5/21/2013)... 2013) Research into genetic features of pulmonary fibrosis ... School of Medicine may lead to improved treatment of ... online by JAMA . , The study found ... some cases of pulmonary fibrosis, a chronic progressive disease ... result of the study, researchers may want to consider ...
(Date:5/21/2013)... agency for scientific and technological research So Paulo Research ... announced an investment estimated in US$ 680 million to ... a period of up to eleven years, subject to ... , Funding for the 17 RIDCs will come from ... support personnel, and infrastructure). Host institutions will participate in ...
Breaking Medicine News(10 mins):Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2[0] Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m.[0] San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank[0] Researchers find genetic risk factor for pulmonary fibrosis[0] Researchers find genetic tie to improved survival time for pulmonary fibrosis[0] Research at the cutting edge of knowledge
(Date:5/20/2013)... planning grant will help establish the Center for Advanced ... University of Illinois at Urbana-Champaign and Worcester Polytechnic Institute ... to research in drying moist, porous materials such as ... chemical products; textiles; and biopharmaceuticals," said Hao Feng, a ... nutrition and the Illinois site director. , According to ...
(Date:5/20/2013)... the University of Bristol and published online today in ... on how the brain and inner ear developed in ... Earth Sciences, together with Tom Hbner from the Niederschsische ... million year old dinosaurs. , The two palaeontologists studied ... : a very young (juvenile) individual of approximately ...
(Date:5/19/2013)... white men and women of European descent inherit common ... toe deformities, including hammer or claw toe. Findings from ... of foot disorders in humansappear in Arthritis Care ... behalf of the American College of Rheumatology (ACR). ... of older adults have foot disorders which may limit ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2Fossil brain teaser 2Blame your parents for bunion woes 2| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |